
Key takeaways:
- Lepu Biopharma has yet to generate product-related revenue, and with only $41 million in cash is desperate for a quick capital injection through an IPO
- Cancer treatment specialist has sold out international portion of its share quota, but domestic portion has met with lukewarm reception